Investopedia: Endo And Forest - Dumpster-Diving In Pharma

While it's true that many stocks trading near 52-week lows belong there, every once in a while an investor can find a real bargain. Endo Pharmaceuticals (Nasdaq:ENDP) and Forest Labs (NYSE:FRX) are both suffering from investor fears about the companies' abilities to withstand generic competition, but could represent solid long-term bargains.

Endo Pharmaceuticals - Bring The Pain?  
Endo Pharmaceuticals has reaped a lot of gain from other people's pain, as drugs like Lipoderm, Opana and Voltaren have been solid sellers in a drug world notably short of new pain medications. Unfortunately, Lipoderm is going off patent in the not-so-distant future and the Street is clearly skeptical regarding the company's ability to grow through that setback.


Click the link for the full article:
http://stocks.investopedia.com/stock-analysis/2011/Endo-And-Forest--Dumpster-Diving-In-Pharma-ENDP-FRX-PFE-NVS-BCR-BSX-GSX0921.aspx